ClinicalTrials.gg
RecruitingNCT05557448Updated Jan 10, 2024

To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

A Phase 2 interventional study of TYNADOTE and Placebo Oral Tablet in Hepatitis, sponsored by Sinew Pharma Inc.. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Sinew Pharma Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hepatitis with a site in Taiwan — 3 open to participants now, 4 under way, none of them phase 3. Hepatitis · Taiwan.

Planned enrollment
21st of 21
24 · median 112
Started
2023
the only one that year
Phase 2
9 of 24
2 open now
Registered
20th of 24
by date
Lead sponsor
2 of 24
Sinew Pharma Inc.

Among the 24 studies in Hepatitis with a site in Taiwan, this one is the 21st largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 2, and was the 20th registered.

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

3 of the 24 studies in Hepatitis with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hepatitis with a site in Taiwan, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of TYNADOTE® in the treatment of acetaminophen overdose

Read the detailed description

This will be a 21-day study to evaluate the efficacy and safety of TYNADOTE® in the treatment of acetaminophen overdose.

After the inform consent is obtained from the subject or his/her legal guardians, the designated assessment will be performed. Subjects who fulfill all the inclusion and exclusion criteria will be eligible to enter the study. Except standard NAC antidote therapy, subjects would be randomized as 1:1 ratio to combine oral TYNADOTE® or placebo.

Eligible subjects will be randomized to receive oral TYNADOTE®/placebo combined iv NAC, and the regimen was listed as below:

The NAC intravenous loading dose is 150 mg/kg over a period of 15 to 60 minutes, followed by an infusion of 12.5 mg/kg per hour over a 4-hour period, and finally an infusion of 6.25 mg/kg per hour over a 16-hour period. Study drug, TYNADOTE® /placebo, should be given a loading dose of 400 mg, followed by 17 maintenance doses of 200 mg every 4 hours (Day 1 to Day 3).

During the treatment period, vital signs will be checked 15 minutes prior to dosing, 30 minutes, 60 minutes, then 2, 4, 8, 12, 24, 36, 48, 60 and 72 hours after first dosing. Blood samples will be collected for liver injuries and function test, including AST, ALT, total bilirubin, direct bilirubin and prothrombin time (INR), prior to dosing, 4 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours after first dosing. Blood samples for drug/metabolites concentration, including TYNADOTE® plasma concentration (trough level), plasma acetaminophen concentration, AAP-Cys and AAP-Cys adducts concentration, prior to dosing, 4 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours and 72 hours after first dosing. Blood samples for biochemistry and hematology, Day 1-3.

After completing the treatment (Day 3), subject will conduct the following evaluations before discharge:

  • Review of adverse events
  • Review of concomitant medications
  • Physical examination On Day 7 and Day 21, subjects should return to the clinics for liver injuries/function follow up and reviewing the adverse events.
03

Conditions studied

  • Hepatitis

Keywords

  • Paracetamol
  • Acetaminophen
  • Acute liver failure
  • N-acetylcysteine
  • Acetaminophen overdose
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Poisoning and hospitalized patients taking acetaminophen.
  • Acute ingestion of more than 150 mg/kg or plasma concentration of Acetaminophen is above the treatment line on single acute acetaminophen overdose nomogram.
  • Male or female with age more than 20 years at Screening.
  • Ability and willingness to provide , adhere to the study visit schedule and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  • Subjects with Sequential Organ Failure Assessment (SOFA) Score higher than 12.
  • Subjects who fulfilled the King's College Hospital (KCH) Criteria for liver transplantation.
  • Subjects who was conscious disturbance.
  • History of allergic response(s) to N-acetylcysteine (NAC), mannitol, sucralose or related drugs.
  • Subject who was unable to take medicine by oral route.
  • Receiving any drug within 30 days prior to first dosing.
  • Subject who had attacked asthma or bronchitis combined with medication therapy within six months prior to enrollment.
  • Donating greater than 150 mL of blood within two months prior to first dosing or donating plasma (e.g. plasmapheresis) within 14 days prior to first dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
  • Subject is pregnant or breastfeeding. Women of must have a negative serum pregnancy test at baseline.
  • Anuria, pulmonary congestion, severe congestive heart failure, brain hemorrhage, or any conditions that in the opinion of the investigator may interfere with the evaluation of study objectives.
  • The combination of poisoning contains acetaminophen and other compound.
  • Body weight less than 50 kg.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Test drug

    200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses

    Drug: TYNADOTE

  • Placebo comparator
    Placebo

    200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses

    Drug: Placebo Oral Tablet

Interventions

  • DrugTYNADOTE

    Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses

  • DrugPlacebo Oral Tablet

    Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses

06

What researchers measure

Primary outcomes

  1. Alanine aminotransferase

    Percentage change from baseline of ALT at Day 3.

    Time frame: Day 3

Secondary outcomes

  1. Alanine aminotransferase

    Percentage change from baseline of ALT at Day 7

    Time frame: Day 7

  2. Alanine aminotransferase

    Percentage change from baseline of AST at Day 3, Day 7

    Time frame: Day 7

  3. Total bilirubin

    Incidence of total bilirubin \> 2.5mg/dL at Day 3, Day 7, Day 21

    Time frame: Day 3, Day 7 and Day 21

  4. Inte- rnational Normalize Ratio

    Incidence of INR \> 1.25 at Day 3, Day 7, Day 21

    Time frame: Day 3, Day 7 and Day 21

  5. Aspartate aminotransferase or Alanine aminotransferase

    Incidence of AST or ALT \>1000 U/L at Day 3, Day 7, Day 21

    Time frame: Day 3, Day 7 and Day 21

  6. Hepatic failure rate (hepatic encephalopathy, ascites, total bilirubin, INR or liver transplantation)

    Hepatic failure rate (hepatic encephalopathy, ascites, total bilirubin \>2.5mg/dL, INR \>1.25, or liver transplantation) at Day 7, Day 21

    Time frame: Day 7 and Day 21

  7. Mortality rate

    Mortality rate at Day 7, Day 21

    Time frame: Day 7 and Day 21

  8. Free plasma acetaminophen-cysteine (AAP-Cys) and AAP-Cys adducts

    The time-interval weighted area under the curve (AUC) of free plasma acetaminophen-cysteine (AAP-Cys) and AAP-Cys adducts within 72-hour treatment period

    Time frame: Day 1-3

  9. TYNADOTE® plasma concentration

    The time-interval weighted area under the curve (AUC) of TYNADOTE® plasma concentration during 72-hour treatment period

    Time frame: Day 1-3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 22 phase 2 interventional studies under Hepatitis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 40. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Sep 28, 2022
StartActual
May 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05557448
Lead sponsor
Sinew Pharma Inc.
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
May 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 10, 2024

Study contacts

ChengHuei Mr. Hsiong, Vice President
Contact
info@sinewpharma.com
+886-2-2788-5365
WanLing Ms. Yang, Research
Contact
wlyang@sinewpharma.com
+886-2-2788-5365

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion